Pulmonary Fibrosis News and Research RSS Feed - Pulmonary Fibrosis News and Research

Nanoparticle exposure can trigger dormant viruses in lung tissue cells

Nanoparticle exposure can trigger dormant viruses in lung tissue cells

Nanoparticles from combustion engines can activate viruses that are dormant in lung tissue cells. This is the result of a study by researchers of Helmholtz Zentrum München, a partner in the German Center for Lung Research, which has now been published in the journal 'Particle and Fibre Toxicology'. [More]
High-fat, low-sugar diet prior to imaging can help reduce uncertainty in diagnosing cardiac sarcoidosis

High-fat, low-sugar diet prior to imaging can help reduce uncertainty in diagnosing cardiac sarcoidosis

Researchers at the University of Illinois at Chicago were able to reduce uncertainty in diagnosing cardiac sarcoidosis by having patients consume a high-fat, low-sugar diet for 72 hours prior to diagnostic imaging. [More]
IPF diagnosis: how do patients feel about the discussion with their physician?

IPF diagnosis: how do patients feel about the discussion with their physician?

IPF (Idiopathic Pulmonary Fibrosis) is a difficult disease to diagnose. Many patients will experience many visits to the doctor and some may even be told they have a different respiratory condition before they finally get the correct diagnosis that... [More]
Researchers crack genetic code of lung tissues to identify novel targets for treating IPF

Researchers crack genetic code of lung tissues to identify novel targets for treating IPF

Researchers cracked the complete genetic code of individual cells in healthy and diseased human lung tissues to find potential new molecular targets for diagnosing and treating the lethal lung disease Idiopathic Pulmonary Fibrosis (IPF). [More]
MILabs to provide Adaptive X-ray CT system to UAB for advancing pulmonary research

MILabs to provide Adaptive X-ray CT system to UAB for advancing pulmonary research

MILabs will provide an advanced U-CTUHR microCT system to the Cystic Fibrosis Research Center (CFRC) at the University of Alabama at Birmingham (UAB). [More]
New study identifies novel target for treatment of Graves' disease and other scarring eye conditions

New study identifies novel target for treatment of Graves' disease and other scarring eye conditions

A new class of therapies may be on the horizon for thyroid eye disease (TED) and other destructive scarring conditions. [More]
Veracyte announces new data suggesting ability of Afirma GEC in thyroid cancer diagnosis

Veracyte announces new data suggesting ability of Afirma GEC in thyroid cancer diagnosis

Veracyte, Inc.today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information – all on a single, robust RNA sequencing platform. [More]
New survey shows majority of patients happy with how physicians manage discussion on IPF diagnosis

New survey shows majority of patients happy with how physicians manage discussion on IPF diagnosis

A diagnosis of IPF is news that few patients want to hear from their physician, but the reality is that approximately 3 million people worldwide are living with idiopathic pulmonary fibrosis (IPF). [More]
British Lung Foundation announces funding for IPF research

British Lung Foundation announces funding for IPF research

Britons are officially three times more likely to die of the incurable lung condition idiopathic pulmonary fibrosis (IPF), than in a road accident. Despite this, the disease is so unheard of and underfunded in research doctors still don’t know what causes it. [More]
Myeloid-derived suppressor cells may serve as biomarkers for idiopathic pulmonary fibrosis

Myeloid-derived suppressor cells may serve as biomarkers for idiopathic pulmonary fibrosis

Researchers at Helmholtz Zentrum München, a partner in the German Center for Lung Research, have discovered that the number of myeloid-derived suppressor cells (MDSC) is increased in the blood of patients with idiopathic pulmonary fibrosis (IPF). [More]
Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients. [More]
VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

Vanderbilt University Medical Center has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF). [More]
New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

Johns Hopkins researchers say they have identified a new disease gene that, when mutated, appears to increase the risk in a small number of people of developing emphysema and a lung-scarring condition known as pulmonary fibrosis. [More]
Scientists use Regeneration Intelligence to assess perturbation status of many signaling pathways

Scientists use Regeneration Intelligence to assess perturbation status of many signaling pathways

Insilico Medicine, Inc in collaboration with scientists from Atlas Regeneration, Inc, Vision Genomics, Inc and Howard University published two research papers on fibrosis in the lung and liver and fibrotic signatures in glaucoma. [More]
Testing lung health online: an interview with Professor Stephen Holgate

Testing lung health online: an interview with Professor Stephen Holgate

In our latest report – The Battle for Breath – the impact of lung disease in the UK, figures suggest that 1 in 5 (around 12.7 million) have been diagnosed with a lung condition in the UK. If you’re over the age of 70, this rises to 1 in 3. [More]
Male hormones can reverse biological drivers of aging, study shows

Male hormones can reverse biological drivers of aging, study shows

Telomerase, an enzyme naturally found in the human organism, is the closest of all known substances to a "cellular elixir of youth." In a recent study, Brazilian and US researchers show that sex hormones can stimulate production of this enzyme. [More]
Advances in inhaled drug delivery: an interview with Dr Robert Clarke

Advances in inhaled drug delivery: an interview with Dr Robert Clarke

Delivering drugs to the lungs via inhalation has a number of potential advantages over traditional routes of administration like pills or injections. For treating pulmonary diseases, the obvious logic we are applying is topical delivery to the airways via inhalation. [More]
New Rutgers research aims at exploring gender differences in lung cancer

New Rutgers research aims at exploring gender differences in lung cancer

Lung cancer is the leading cause of cancer death in both men and women. Lung cancer diagnoses have more than doubled among females in the past 38 years, while having fallen 29 percent among males, according to the American Lung Association. [More]
Wresting back control of CHI3L1 protein could stave off cancer spread in mice

Wresting back control of CHI3L1 protein could stave off cancer spread in mice

For cancer to spread, the cells that take off into the bloodstream must find a tissue that will permit them to thrive. They don't just go looking, though. Instead, they actively prepare the tissue, in one case by co-opting a protein that suppresses defenses the body would otherwise mount. [More]
Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF). [More]
Advertisement
Advertisement